Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Deferred Revenue: 2021-2024

Historic Current Deferred Revenue for ARS Pharmaceuticals (SPRY) over the last 3 years, with Dec 2024 value amounting to $557,000.

  • ARS Pharmaceuticals' Current Deferred Revenue was N/A to $526,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $526,000, marking a year-over-year change of. This contributed to the annual value of $557,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Current Deferred Revenue of $557,000 as of FY2024, which was down 82.24% from $3.1 million recorded in FY2022.
  • Over the past 5 years, ARS Pharmaceuticals' Current Deferred Revenue peaked at $3.1 million during FY2022, and registered a low of $557,000 during FY2024.
  • For the 2-year period, ARS Pharmaceuticals' Current Deferred Revenue averaged around $1.8 million, with its median value being $1.8 million (2022).
  • Data for ARS Pharmaceuticals' Current Deferred Revenue shows a peak YoY soared of 115.31% (in 2022) over the last 5 years.
  • ARS Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $1.5 million in 2021, then surged by 115.31% to $3.1 million in 2022, then reached $557,000 in 2024.